Testing ALE.F02 for new kidney inflammation from vasculitis
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new medicine called ALE.F02 for people newly diagnosed with a type of kidney inflammation called rapidly progressive glomerulonephritis (RPGN) caused by ANCA vasculitis. The goal is to see if it can help rescue kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were diagnosed with RPGN from ANCA vasculitis within the last 45 days.
- Your kidney function (eGFR) is between 10 and 50 mL/min/1.73 m2.
- You are willing to have a kidney biopsy or have had one within the last 45 days.
- You weigh 130 kg (about 286 lbs) or less.
- You are not on dialysis or have not had it in the last 7 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NM8074 for a type of blood vessel inflammation called ANCA-associated vasculitis. It's for people whose vasculitis is active and needs a stronger treatment like cyclophosphamide or rituximab.
This trial tests an investigational medication for two rare kidney conditions that cause inflammation and protein in the urine. It aims to see if the drug is safe and helps control the disease, potentially slowing kidney damage.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
This study tests a new ADARx medicine in Chinese adults with specific types of kidney disease (IgAN, C3G, or IC-MPGN). The goal is to see if this treatment can slow kidney damage and help preserve kidney function.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
Hear when a new Glomerulonephritis Rapidly Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.